Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:43:35 EST Mon 02 Nov 2026
Enter Symbol
or Name
USA
CA



Q:PLSE - PULSE BIOSCIENCES INC - https://investors.pulsebiosciences.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PLSE - Q0.553.49·53.760.353.49+1.252.4121.46,2912,30352.40  53.85  51.3258.90  12.5613:22:57Oct 2915 min RT 2¢

Recent Trades - Last 10 of 2303
Time ETExPriceChangeVolume
13:22:57Q53.491.25100
13:22:56Q53.59681.356812
13:22:25Q53.59811.358110
13:22:01Q53.6251.38521
13:21:34Q53.50521.2652135
13:21:34Q53.631.391
13:21:28Q53.701.461
13:21:06Q53.701.461
13:21:02Q53.681.4410
13:20:34Q53.771.531

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-10-29 13:05U:PLSENews ReleasePulse Biosciences to Present at Stifel 2026 Healthcare Conference
2026-10-22 16:05U:PLSENews ReleasePulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026
2026-10-14 07:00U:PLSENews ReleasePulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
2026-10-09 16:05U:PLSENews ReleasePulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-08 07:00U:PLSENews ReleasePulse Biosciences' nPulse(TM) Technology to be Featured at the 21st Annual International VT Symposium 2026
2026-10-07 07:00U:PLSENews ReleasePulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse(TM) Cardiac Catheter System for Atrial Fibrillation Treatment
2026-09-15 07:00U:PLSENews ReleasePulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse(TM) Vybrance(TM) Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
2026-09-04 07:00U:PLSENews ReleasePulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-18 07:00U:PLSENews ReleasePulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-06 16:05U:PLSENews ReleasePulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
2026-07-30 16:05U:PLSENews ReleasePulse Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
2026-07-29 07:00U:PLSENews ReleasePulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
2026-07-21 16:05U:PLSENews ReleasePulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
2026-07-15 16:05U:PLSENews ReleasePulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-10 07:00U:PLSENews ReleasePulse Biosciences, Inc. Announces Planned Redemption of Warrants
2026-05-27 16:05U:PLSENews ReleasePulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
2026-05-12 07:00U:PLSENews ReleaseATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
2026-05-08 07:00U:PLSENews ReleasePulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
2026-05-04 07:00U:PLSENews ReleasePulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
2026-04-25 13:00U:PLSENews ReleasePulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse(TM) Cardiac Catheter System at Heart Rhythm 2026